Reference : Pharma-clinics. Le medicament du mois. Premelle (oestrogenes conjugues + medroxyproge...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Reproductive medicine (gynecology, andrology, obstetrics)
Pharma-clinics. Le medicament du mois. Premelle (oestrogenes conjugues + medroxyprogesterone).
[fr] Pharma-clinics. Drug of the month. Premelle (conjugated estrogens + medroxyprogesterone
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Revue Médicale de Liège
Hopital de Baviere
Yes (verified by ORBi)
[en] Drug Combinations ; Estrogen Replacement Therapy/methods ; Estrogens, Conjugated (USP)/therapeutic use ; Female ; Humans ; Medroxyprogesterone/therapeutic use ; Middle Aged ; Premenopause/drug effects ; Progesterone Congeners/therapeutic use
[en] Premelle, commercialised by Wyeth-Lederle, is a combination of conjugated estrogens 0.625 mg and medroxyprogesterone acetate 5 mg which is indicated in the treatment of menopause-associated problems, among which vasomotor symptoms, atrophic vaginitis and/or urethritis, and in the prevention and treatment of post-menopausal osteoporosis. It is presented in two formulations, Premelle cyclic 5 and Premelle 5. The former, in which the progestagen is only given during the last 14 out of 28 days of the treatment cycle, is accompanied by regular bleeding and thus preferably indicated during perimenopause whereas the latter, in which the progestagen is given continuously and results in amenorrhea, is mostly indicated after menopause in order to improve long-term compliance.

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.